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Abstract: Faecal microbiota transfer (FMT) consists of the introduction of new microbial communities
into the intestine of a patient, with the aim of restoring a disturbed gut microbiota. Even though it is
used as a potential treatment for various diseases, it is unknown how the host mucosa responds to
FMT. This study aims to investigate the colonic mucosa gene expression response to allogenic (from
a donor) or autologous (own) FMT in patients with irritable bowel syndrome (IBS). In a recently
conducted randomised, double-blinded, controlled clinical study, 17 IBS patients were treated with
FMT by colonoscopy. RNA was isolated from colonic biopsies collected by sigmoidoscopy at baseline,
as well as two weeks and eight weeks after FMT. In patients treated with allogenic FMT, predominantly
immune response-related gene sets were induced, with the strongest response two weeks after the
FMT. In patients treated with autologous FMT, predominantly metabolism-related gene sets were
affected. Furthermore, several microbiota genera showed correlations with immune-related gene sets,
with different correlations found after allogenic compared to autologous FMT. This study shows that
the microbe–host response is influenced by FMT on the mucosal gene expression level, and that there
are clear differences in response to allogenic compared to autologous FMT.
Keywords: faecal microbiota transplantation; irritable bowel syndrome; gene expression; microbiota;
host-microbe interaction
1. Introduction
Faecal microbiota transfer (FMT) consists of the introduction of a new microbiota into the intestine
of a patient, with the aim of restoring a disturbed gut microbiota. FMT has proven to be a safe and
long-lasting treatment for patients with recurrent Clostridioides difficile infection, with cure rates of
approximately 90% [1]. Faecal microbiota transfer has also shown to have positive effects in other
diseases, such as ulcerative colitis (UC) and metabolic syndrome [2–6]. In addition, FMT seems to
be a promising treatment option for irritable bowel syndrome (IBS). Irritable bowel syndrome is a
common chronic gastrointestinal disorder, with an estimated worldwide prevalence of 6–18% [7,8], in
which patients suffer from abdominal pain, cramps, and altered gut motility. The pathophysiology
of IBS is unknown, but it is generally accepted that the microbiota–gut–brain axis plays a key role
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in this disorder. Aberrations along this axis include visceral hypersensitivity, altered gut microbiota,
and low-grade inflammation. Three recent placebo-controlled studies have studied the effect of
FMT in IBS. Johnsen et al. administered FMT by whole colonoscopy, and found more responders
in the group of IBS patients receiving donor material (allogenic FMT) than in the group receiving
their own stool back (autologous FMT) (p = 0.049) [9]. Halkjaer et al. administered FMT orally via
capsules, and found greater symptom reduction after the intake of inert placebo capsules (without
stool) compared to the intake of capsules containing donor faecal material [10]. We recently conducted
a randomised, double-blinded, placebo-controlled clinical study, in which 17 IBS patients received
FMT by colonoscopy [11]. Whereas there were no significant differences in symptoms between the
allogenic and the autologous groups, possibly due to the small group size, only in the allogenic group
did the symptom scores improve significantly after FMT compared to the baseline.
Even though FMT is used as a potential treatment for various diseases, there is limited knowledge
on how the host mucosa responds to the introduction of a new gut microbiota. In a recent study, the
impact of autologous FMT on mucosa gene expression was characterized in six antibiotic-treated,
healthy individuals [12]. However, there is no research on the effect of FMT in IBS, and knowledge on
mode-of-action is pivotal in order to develop a more targeted treatment approach.
The aim of the current study is to examine the effect of FMT on the gene expression in the colon
mucosa of IBS patients after the infusion of allogenic (from a healthy donor) compared to autologous
(own) faecal material into the colon. To the best of our knowledge, this is the first study to investigate
how the host mucosa responds to the introduction of a new gut microbiota in IBS patients in a
controlled fashion.
2. Materials and Methods
2.1. Study Design
Seventeen patients with IBS were treated with faecal material from two healthy donors (allogenic
FMT) or with their own faecal microbiota (autologous FMT), as described in detail in the previously
published study by Holster et al. [11]. In short, two healthy donors, selected based on a high abundance
of butyrate-producing bacteria in their faecal samples, were carefully screened and only included if they
did not fulfill any of the strict exclusion criteria listed in Holster et al. [11]. The faecal transplant was
administered by whole colonoscopy into the caecum (30 g of stool in 150 mL sterile saline). Two weeks
before the FMT (baseline) as well as two and eight weeks after the FMT, the participants underwent a
sigmoidoscopy, and biopsies were collected at a standardised location (20–25 cm from the anal verge,
at the crossing with the arteria iliaca communis) from an uncleansed sigmoid. All subjects gave their
written informed consent before participation in the study. The study was conducted according to the
principles of the Declaration of Helsinki and its revisions, and ethical approval was obtained from
the Central Ethical Review Board of Uppsala, Sweden (registration number 2013/180). The trial was
registered at ClinicalTrials.gov (NCT02092402) on March 20, 2014.
2.2. RNA Isolation and Microarray Processing
Biopsies stored in RNAlater (Invitrogen by ThermoFisher, Waltham, MA, USA) at −80 ◦C were
used to isolate total RNA. RNA was isolated using Qiagen RNeasy Mini Kit (Qiagen, Venlo, The
Netherlands), quantified using NanoDrop, and quality was checked with the Agilent 2100 bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). Samples were only included for further analyses in cases
of intact bands corresponding to 18S and 28S ribosomal subunits, as well as absence of chromosomal
peaks or RNA degradation products. Total RNA (100 ng) was labelled with the Whole-Transcript
Sense Target Assay (Affymetrix, Life Technologies, Bleiswijk, the Netherlands; P/N 900652) and
hybridized to whole genome Affymetrix Human Gene 2.1 ST arrays (Affymetrix, Santa Clara, CA,
USA). Sample labelling, hybridization to chips, and image scanning were performed according to
the manufacturer’s instructions. Quality control and the data analysis pipeline have been described
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in detail previously [13]. Briefly, normalized expression estimates of probe sets were computed by
the robust multiarray analysis (RMA) algorithm [14], as implemented in the Bioconductor package
AffyPLM. Probe sets were redefined using current genome information according to Dai et al. [15],
based on genome annotations provided by the Entrez Gene database, which resulted in the profiling of
29,635 unique genes (custom CDF v23).
Differentially expressed probe sets (genes) were identified by using linear models (package
limma) and an intensity-based, moderated t-statistic [16,17]. The repeated, parallel design of the
study was taken into account by coding a nested model matrix. To allow for the heterogeneity
in gene expression profiles in samples obtained from the same patient, a heteroskedastic model
was fitted by computing weights for each sample individually that were included in the linear
model [18,19]. Comparisons of gene expression data in colonic biopsies between two weeks after FMT
and baseline, and eight weeks after FMT and baseline, respectively, were made for both the allogenic
and autologous group (within-group comparisons). Additionally, baseline-corrected gene expression
data was directly compared between the allogenic and autologous group at two and eight weeks after
FMT (between-group comparisons). The p-values were corrected for multiple testing, according to
Benjamini and Hochberg [20,21].
2.3. Biological Interpretation of Array Data
Changes in gene expression were related to biologically meaningful changes using gene set
enrichment analysis (GSEA) [22]. It is well accepted that GSEA has multiple advantages over analyses
performed on the level of individual genes [22–24]. Gene set enrichment analysis evaluates gene
expression on the level of gene sets that are based on prior biological knowledge—e.g., published
information about biochemical pathways or signal transduction routes—allowing more reproducible
and interpretable analysis of gene expression data. As no gene selection step (fold change or p-value
cut-off) is used, GSEA is an unbiased approach. A GSEA score is computed based on all genes in the
gene set, which boosts the signal-to-noise ratio and allows the detection of affected biological processes
that are due to only subtle changes in the expression of individual genes. This GSEA score, called
a normalised enrichment score (NES), can be considered as a proxy for gene set activity. Gene sets
were retrieved from the expert-curated KEGG pathway database [25]. Only gene sets comprised of
more than 15 and fewer than 500 genes were taken into account. For each comparison, genes were
ranked on their t-value, which was calculated by the moderated t-test. The statistical significance
of GSEA results was determined using 10,000 permutations. The GSEA results were visualized for
visualization and interpretation using the package clusterProfiler [26] and the Enrichment Map plugin
for Cytoscape [27]. For each time point, a separate grid was made that was used for the within- and
between-group comparisons.
2.4. Correlations between Pathway Activity and Mucosal Microbiome Data
To obtain insight into the correlations between changes in pathway activity versus the
mucosa-adherent microbiota, integrative multivariate correlation analysis was performed based
on data from the individual samples, using the package mixOmics [28]. Samples from the allogenic
and autologous group were analysed separately, but included those obtained at baseline, as well as
two and eight weeks after FMT. Unsupervised, single sample pathway scores were calculated by the
gene set variation analysis (GSVA) algorithm [29], using the same pathways as used for GSEA. As
input for the correlation matrix, gene sets were used that were significantly differentially regulated
(p < 0.01) within either the allogenic or autologous group. Mucosal-adherent microbiota was analysed
from colonic biopsies collected from an uncleansed sigmoid two weeks before FMT, as well as two
and eight weeks after FMT, as reported previously by Holster et al. [11]. In short, microbial DNA
from the mucosal samples (see Section 2.1) was isolated using repeated bead beating [30] with some
adjustments, including a proteinase K incubation prior to the mechanic cell disruption, and use of
a Maxwell extraction robot (Maxwell 16 Tissue LEV Total RNA Purification Kit; Promega, Madison,
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WI, United States). The Human Intestinal Tract Chip (HITChip), a customized Agilent microarray,
was used to assess the mucosal microbiota composition, as previously described [31], with minor
modifications [2]. The hybridization signals were normalized and summarized to 130 genus-like
phylogenetic groups (level 2, 0.90% 16S rRNA gene sequence similarity), referred to as species and
relatives [31] (See Supplemental File for HitChip data).
The compositional, genera-level data were centered log-ratio (clr) transformed before subjected
to correlation analyses [28,29]. The correlation between the two datasets (pathway activity and
microbiome composition) was analysed by partial least squares (PLS) regression (canonical mode),
accounting for repeated measurements obtained from the same patient. Results were visualized in
clustered image maps [32].
2.5. Protein Isolation
Biopsies stored in AllProtect (Qiagen) at −80 ◦C, which were taken at the same time points as for
RNA isolations, were used for protein isolation. The tissue was homogenized using the Tissuelyser
(LT, Qiagen) for 3 min at 50 Hz in 250 µL RIPA buffer (Merck, Darmstadt, Germany), including 1×
Protease Inhibitor Cocktail (ThermoFisher Scientific). The homogenised mixture was centrifuged for
5 min at 4 ◦C at 10,000 rpm (9500×g), and the supernatant was aliquoted and stored at −80 ◦C until
further analysis.
2.6. Cytokine Analysis
The cytokines IFNγ, IL1-b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and TNFαwere measured in
duplicates with U-PLEX Biomarker Group 1 (hu) assays (K15067L-1, Meso Scale Discovery), according
to the manufacturer’s protocol. The concentrations of cytokines were normalized by the total protein,
determined by a Coomassie (Bradford) protein assay kit (23200, ThermoScientific) and expressed as
picogram (pg)/mg total protein. Samples with cytokine concentrations under detection level were
considered to be 0 pg/mg total protein. Principal component analysis was performed on the cytokine
concentrations using the prcomp-function in R with the scale set to “true”.
2.7. Data Availability
Array data have been submitted to the Gene Expression Omnibus under accession
number GSE138297.
3. Results
3.1. Subjects
The clinical outcome and microbiota analysis of the FMT intervention has been described in detail
in the previously published study of Holster et al. [11]. Seventeen IBS patients were treated with
FMT, of which eight patients received faecal material from a healthy donor (allogenic FMT), and nine
received their own faecal material back (autologous FMT) (for demographics of the study population,
see Table 1). One of the participants dropped out due to procedure-related adverse effects, and another
participant chose not to continue with the sigmoidoscopies after the FMT (both from the autologous
group). In total, colonic biopsies from 15 subjects at three time points were available for analysis.
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Table 1. Baseline characteristics of irritable bowel syndrome (IBS) patients included in this study.
Allogenic (n = 8) Autologous (n = 7) p-Value
Age,
median (IQR) 34 (27–42) 38 (32–45) 0.42
Sex,
m/f 5/3 3/4 0.62
BMI (kg/m2),
median (IQR)
20.9 (20.2–25.1) 23.8 (20.5–24.7) 0.94
Classification,
IBS-D/IBS-C/IBS-M 5/1/2 4/2/1 1.0/0.57/1.0
Post-infectious IBS 4 3 1.0
Disease duration: unknown/1–5 y/5 y 0/4/4 1/3/3 0.47/1.0/1.0
Concomitant medication 7 5 0.57
Gut-related medication 3 3 1.0
Laxatives 1 2 * 1.0
Anti-diarrhoeal 1 1 1.0
Anti-spasmodic 1 1 1.0
Antidepressants 5 2 0.31
SSRIs 5 0 0.03
NaSSAs 0 1 0.47
SSNRIs 0 1# 0.47
TCAs 0 1# 0.47
IQR: interquartile range, BMI: body mass index, D: diarrhoea, C: constipation, M: mixed classification, SSRI:
serotonin-reuptake inhibitor, NaSSA: noradrenergic and specific serotonergic antidepressant, SSNRI: selective
serotonin–noradrenalin-reuptake inhibitor, TCA: tricyclic antidepressant. * One participant took two different types
of laxatives. #One participant took both SSNRI and TCA. This table has been modified from Holster et al. [11].
3.2. Individually Differentially Expressed Genes
No large impact of FMT on individual genes was found. The mean fold changes (FC) were
calculated between the baseline versus two and eight weeks after FMT, respectively, in both the allogenic
and the autologous group. Only genes with FC >1.5 and <−1.5 were considered as differentially
expressed. In the allogenic group, thirty genes were differentially expressed, with p < 0.005 two
weeks after FMT compared to the baseline (Supplemental Table S1), and 19 genes eight weeks after
FMT compared to the baseline (Supplemental Table S2). No genes were significantly expressed
after correction for multiple testing (false discovery rate, FDR < 0.05). In the autologous group, 52
differentially expressed genes with p < 0.005 were found two weeks after FMT, compared to the
baseline (Supplemental Table S3, no significant genes after multiple testing), and 148 after eight weeks
(Supplemental Table S4). After correction for multiple testing, 26 genes were significantly differentially
expressed (FDR < 0.05) after eight weeks (Supplement Table S5).
When comparing the allogenic FMT group to the autologous FMT group, 149 genes were
differentially expressed two weeks after FMT with p < 0.005 (Supplemental Table S6). Eight weeks
after FMT, 191 genes were significantly differentially expressed (p < 0.005; Supplemental Table S7). No
genes were significantly differentially expressed after correction for multiple testing (FDR < 0.05) in
both comparisons.
3.3. Gene Set Enrichment Analysis
3.3.1. Differentially Expressed Gene Sets after Faecal Microbiota Transfer
Gene set enrichment analysis (GSEA) was performed to elucidate the biological processes that
were changed upon the allogenic and autologous FMT treatments, and clear differences between the
both groups were found. All pathways that were significantly differentially regulated in at least one of
the six different comparisons (FDR < 0.05) are shown in Figure 1. In the allogenic group, the strongest
effect was observed two weeks after FMT, where pathways were mostly upregulated compared to
the baseline (Figure 1A). After eight weeks, a few of these pathways were still upregulated, while
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others were downregulated (Figure 1A). In the group receiving autologous FMT, fewer gene sets were
significantly up- or down-regulated, and different gene sets were affected than in the group receiving
allogenic FMT (Figure 1B). The direct comparison between the allogenic and the autologous group
(baseline-corrected data) is shown in Figure 1C. A considerably larger number of pathways showed
higher expression in the allogenic group compared to in the autologous group two weeks after FMT,
and to a lesser extent, eight weeks after FMT. A different set of pathways showed lower expression in
the allogenic group compared to the autologous group after eight weeks.
3.3.2. Enrichment Maps
Next, enrichment maps, network-based visualizations of the GSEA results, were generated to
identify common clusters of regulated pathways (Figure 2 and Figure 4). Since the focus of this study
was on the differences between the treatments, we first selected the gene sets that were differentially
regulated (FDR < 0.25) between the allogenic and autologous FMT after two (for Figure 2) or eight
weeks (for Figure 4). These gene sets were used as input for the enrichment maps, and for better
visualization, only gene sets with FDR < 0.05 in the three depicted comparisons are shown in Figure 2
and Figure 4.
Two Weeks after Faecal Microbiota Transfer
The enrichment map generated by comparing the response of the allogenic group to the autologous
group two weeks after FMT revealed that the genes coding for immune-related pathways were higher
expressed, whereas those coding for metabolic pathways were lower expressed in the allogenic group
compared to the autologous FMT group (Figure 2A, see Supplemental Figure S1 for all gene set names).
Figure 2B depicts the same enrichment map for the within-group comparison in the allogenic group
after two weeks, compared to baseline. It shows that these immune-related pathways were upregulated
in the allogenic FMT group, and were not affected in the autologous FMT group (Figure 2C). Figure 2C
shows the within-group comparison for the autologous group at two weeks compared to baseline.
Here, gene sets involved in cellular metabolism were upregulated, while they were not changed in the
allogenic FMT group (Figure 2B).
The gene sets within the largest cluster of immune-related gene sets were generally representative
of the activation of the adaptive immune response (allograft rejection, autoimmune thyroid disease,
asthma, antigen processing and presentation, graft-versus-host disease, intestinal immune network for
Immunoglobulin A production, inflammatory bowel disease, Th1 and Th2 cell differentiation, Th17
cell differentiation, type I diabetes mellitus, and viral myocarditis). The large number of connections
between these gene sets imply that a common set of key genes (core enriched genes) was induced. The
fold changes of these core enriched genes in both groups, as well as on individual levels, are shown
in Figure 3.
In addition, Figure 3 shows which subject received FMT from which donor. The host response to
the two different donors did not seem to differ notably.
Eight Weeks after Faecal Microbiota Transfer
Eight weeks after FMT, the allogenic group still showed an increased expression of immune-related
gene sets compared to the autologous group (Figure 4A; see Supplemental Figure S2 for all gene set
names), which seemed to be, to a large extent, attributable to a downregulation of immune-related gene
sets in the autologous group eight weeks after FMT compared to baseline (Figure 4C). The upregulation
of the gene sets of immune-related pathways two weeks after allogenic FMT was no longer as strong
at eight weeks after FMT compared to the baseline (Figure 4B). More gene sets involved in cellular
metabolism were downregulated in the allogenic group compared to the autologous group eight weeks
after FMT (Figure 4A) than after two weeks (Figure 2A). The gene sets for these metabolism-related
pathways were downregulated in the allogenic group and upregulated in the autologous group eight
weeks after FMT, compared to the baseline (Figure 4B,C).
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Figure 1. Differentially expressed gene sets after faecal microbiota transfer (FMT). (A) Allogenic FMT 
(within-group comparisons). (B) Autologous FMT (within-group comparisons). (C) Allogenic versus 
autologous FMT (two and eight weeks after FMT, baseline-corrected). Gene set enrichment analysis 
(GSEA) was performed. Each row depicts a gene set that was significantly differentially regulated in 
one of the six comparisons (false discovery rate, FDR < 0.05), with the corresponding normalised 
enrichment score (NES) value on the y-axis. The colour of the dot indicates the statistically significant 
FDR value of the corresponding gene set in that specific comparison. The size of the dot reflects the 
gene ratio, which represents the number of enriched genes in the gene set. 
Figure 1. Differentially expressed gene sets after faecal microbiota transfer (FMT). (A) Allogenic FMT
(within-group comparisons). (B) Autologous FMT (within-group comparisons). (C) Allogenic versus
autologous FMT (two and eight weeks after FMT, baseline-corrected). Gene set enrichment analysis
(GSEA) was performed. Each row depicts a gene set that was significantly differentially regulated
in one of the six comparisons (false discovery rate, FDR < 0.05), with the corresponding normalised
enrichment score (NES) value on the y-axis. The colour of the dot indicates the statistically significant
FDR value of the corresponding gene set in that specific comparison. The size of the dot reflects the
gene ratio, which represents the number of enriched genes in the gene set.
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Figure 2. Enrichment maps of the gene set changes two weeks after FMT. (A) Allogenic versus 
autologous FMT (baseline-corrected). (B) Allogenic FMT (within-group comparison). (C) Autologous 
FMT (within-group comparison). Nodes represent KEGG gene sets, and the edges between the nodes 
represent their similarity. Red nodes indicate enriched (increased expression of) gene sets, and blue 
nodes indicate suppressed (decreased expression of) gene sets. Node size represents the number of 
genes in the gene set, and the thickness of the edges indicates the degree of overlap between the two 
connected gene sets (nodes). The gene sets are manually grouped according to their biological 
functions among these gene sets. See Supplemental Figure S1 for the enrichment map including all 
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Figure 2. Enrichment maps of the gene set changes two weeks after FMT. (A) Allogenic versus
autologous FMT (baseline-corrected). (B) Allogenic FMT (within-group comparison). (C) Autologous
FMT (within-group comparison). Nodes represent KEGG gene sets, and the edges between the nodes
represent their similarity. Red nodes indicate enriched (increased expression of) gene sets, and blue
nodes indicate suppressed (decreased expression of) gene sets. Node size represents the number of
genes i the gen s , a d the thickness of the edges indicates the degree of ov rlap between the
two connected gene s ts (nodes). The gene sets are manually grouped according to their bio ogical
functions among these gene sets. See Supplemental Figure S1 for the enrichment map including all
the names of the gene sets. Gene sets that were differentially regulated (FDR < 0.25) between the
allogenic and autologous FMT after two weeks were used as input for the enrichment map, and for
better visualization, only the gene sets with FDR < 0.05 from the three depicted comparisons are shown.
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the log2 fold changes after allogenic FMT compared to baseline (A) and after autologous FMT 
compared to baseline (B), respectively. The two last panels show the log2 fold changes per subject 
after allogenic and autologous FMT, respectively. The lines above the subjects receiving allogenic 
FMT indicate which subject received FMT from which donor. 
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Figure 3. Core enriched genes shared by the gene sets in the largest network of the enrichment map
two weeks after FMT. The log2 fold changes of the g nes commonly induced in the gene sets within t e
larges cluster of immune-related gene sets (Figure 2A) are shown. The first two columns show th
log2 fold changes after all genic FMT compared to baseline (A) and after aut logous FMT compared to
baseline (B), respectively. The two last panels show the log2 fold changes per subject after allogenic
and autologous FMT, respectively. The lines above the subjects receiving allogenic FMT indicate which
subject received FMT from which donor.
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Figure 4. Enrichment maps of gene sets changed eight weeks after FMT. (A) Allogenic versus 
autologous FMT (baseline-corrected). (B) Allogenic FMT (within-group comparison). (C) Autologous 
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Figure 4. Enrichment maps of gene sets changed eight weeks after FMT. (A) Allogenic versus
autologous FMT (baseline-corrected). (B) Allogenic FMT (within-group comparison). (C) Autologous
FMT (within-group comparison). Nodes represent KEGG gene sets, and the edges between the nodes
represent their similarity. Red nodes indicate enriched (increased expression of) gene sets, and blue
nodes indicate suppressed (decreased expression of) gene sets. Node size represents the number of
genes in the gene set, and the thickness of the edges indicates the degree of overlap between the two
connected gene sets (nodes). The gene sets are manually grouped according to their biological functions
among these gene sets. See Supplemental Figure S2 for the enrichment map including the names
of all the gene sets. Gene sets that were differentially regulated (FDR < 0.25) between the allogenic
and autologous FMT after eight weeks were used as input for the enrichment map, and for better
visualization, only the gene sets among those with FDR < 0.05 in the three depicted comparisons
are shown.
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3.4. Microbiome–Gene Set Correlations
In order to generate individual gene set activity scores, gene set variation analysis (GSVA) was
performed. Gene sets differentially expressed in any of the direct comparisons (allogenic vs. autologous
FMT, two and eight weeks after FMT, p < 0.01) were correlated to the mucosa-adherent microbiota in
both the allogenic FMT group (Figure 5A) and the autologous FMT group (Figure 5B). Hierarchical
clustering separated the gene sets in immune-related and metabolism-related pathways. Cluster
I includes the bacterial genera that were positively correlated with the immune-related pathways,
while cluster II reveals the genera that were negatively correlated with the immune-related pathways
in the allogenic FMT group (for individual bacterial genera names, see Table 2). In the autologous
FMT group, clusters III and IV include the genera that were positively or negatively correlated to
the immune-related pathways, respectively (Table 2). A large set of bacterial genus-like groups were
found to correlate with the immune-related pathways. Interestingly, bacteria belonging to Anaerostipes
caccae and Coprococcus eutactus were found in both FMT groups to correlate positively with these
pathways. Both of these are well-known butyrate producers, with bacteria related to A. caccae having
the property to form this intestinal signalling molecule not only from sugars, but also from acetate
and lactate. Conversely, many of the bacteria that negatively correlated with the immune pathways in
the autologous FMT were pathobionts belonging to the Gram-negative proteobacteria (Helicobacter,
Pseudonomas, Yersinia, Proteus, and Vibrio) as well as various Lactobacillus genera that are capable of
producing lactate and acetate.
3.5. Cytokines
In order to study whether these results were mirrored at the protein level, the concentrations
of several cytokines in the biopsies, obtained at the same time points, were measured. IL-2, IL-4,
IL-12p70, and IL-13 were excluded from analysis, due to too many samples with concentrations under
the detection level. The levels of the detectable cytokines, tumour necrosis factor (TNF)-alpha, IL-1beta,
IL-6, IL-8, IL-10, and IFN-gamma, were not significantly different between and within the groups
receiving allogenic or autologous FMT (Supplemental Figure S3A–F). Supplemental Figure S3G,H
show a multivariate analysis of these detectable cytokines for the allogenic group and the autologous
FMT group, respectively. Also, no clear differences could be observed here.
4. Discussion
It is not yet known how FMT, the transfer of donor faecal material with the aim of modulating
the gut microbiota of the recipient, affects the host mucosal response. In this study, the host response
from IBS patients upon allogenic FMT (receiving donor material) and autologous FMT (receiving own
faecal material back) was investigated. For the biological interpretation of the data, and to improve
signal-to-noise ratio, gene set enrichment analysis was performed. This showed that allogenic FMT
from a healthy donor evoked a different mucosal response than autologous FMT. Introduction of a
new faecal microbiota ecosystem seemed to provoke a predominantly immune-related response. This
response was especially strong two weeks after FMT, and was partially persisting after eight weeks.
Administration of the subjects’ own faecal material induced a less profound response after two weeks,
but showed an effect on both the metabolism and the immune system eight weeks after FMT compared
to the baseline.
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Figure 5. Heat map of correlations between mucosa-adherent microbiota and gene sets affected by FMT. (A) Allogenic FMT. (B) Autologous FMT. Gene sets differentially 
expressed in any of the direct comparisons (allogenic vs. autologous FMT, two and eight weeks after FMT, p < 0.01) were included. Correlations with correlation coefficient 
(r) > 0.5 are shown. GSVA: gene set variation analysis.
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Figure 5. Heat map of correlations between mucosa-adherent microbiota and gene sets affected by FMT. ( ) Allogenic FMT. (B) Autologous FMT. Gene sets
differentially expressed in any of the direct comparisons (allogenic vs. autologous FMT, two and eight weeks after FMT, p < 0.01) were included. Correlations with
correlation coefficient (r) > 0.5 are shown. GSVA: gene set variation analysis.
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Table 2. Bacterial genera positively (+) or negatively (−) correlating to immune-related gene sets
affected by FMT.
Allogenic FMT Autologous FMT
Cluster I (+) Cluster II (−) Cluster III (+) Cluster IV (−)
Peptococcus niger et rel. Propionibacterium Anaerovorax odorimutanset rel. Aneurinibacillus
Enterobacter aerogenes et
rel. Bacteroides fragilis et rel.
Phascolarctobacterium
faecium et rel. Bilophila et rel.
Xanthomonadaceae Gemella Clostridium orbiscindens etrel.
Lactobacillus plantarum et
rel.
Clostridium nexile et rel. Granulicatella Sporobacter termitidis etrel. Clostridium (sensu stricto)
Outgrouping clostridium
cluster XIVa Dialister
Oscillospira guillermondii
et rel. Uncultured Chroococcales
Eubacterium siraeum et rel. Tannerella et rel. Oxalobacter formigenes etrel. Fusobacteria
Clostridium sphenoides et
rel.
Peptostreptococcus
anaerobius et rel.
Faecalibacterium
prausnitzii et rel. Pseudomonas
Clostridium difficile et rel. Akkermansia Ruminococcus bromii et rel. Uncultured Mollicutes
Anaerostipes caccae et rel. Parabacteroides distasoniset rel. Clostridium cellulosi et rel. Novosphingobium
Coprococcus eutactus et rel. Clostridium leptum et rel. Ruminococcus lactaris etrel. Wissella et rel.
Bryantella formatexigens et
rel. Ruminococcus bromii et rel.
Ruminococcus callidus et
rel. Yersinia et rel.
Veillonella Allistipes et rel. Coprococcus eutactus et rel. Peptococcus niger et rel.
Dorea formicigenerans et
rel.
Subdoligranulum variable
at rel. Eubacterium hallii et rel. Proteus et rel.
Papillibacter
cinnamivorans et rel. Vibrio
Bacteroides uniformis et rel. Moraxellaceae
Clostridium sphenoides et
rel. Prevotella ruminicola et rel.
Outgrouping clostridium
cluster XIVa
Lactobacillus catenaformis
et rel.
Ruminococcus obeum et rel. Micrococcaceae
Clostridium symbiosum et
rel. Helicobacter
Anaerostipes caccae et rel. Clostridium felsineum etrel.
Methylobacterium
Lactobacillus salivarius et
rel.
Aeromonas
Desulfovibrio et rel.
Clostridium thermocellum
et rel.
Campylobacter
Asteroleplasma et rel.
Bacillus
Brachyspira
Actinomycetaceae
Aerococcus
Anaerobiospirillum
Aquabacterium
Atopobium
Bulleidia moorei et rel.
Catenibacterium mitsuokai
et rel.
Corynebacterium
Megasphaera elsdenii et rel.
Mitsuokella multiacida et
rel.
Peptostreptococcus
anaerobius et rel.
Xanthomonadaceae
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Among the cluster of gene sets found to be significantly upregulated after allogenic FMT were
“allograft rejection” and “graft versus host disease”. This suggests that the host regards the new
microbiota as foreign and activates defence or rejection mechanisms. Whether it is beneficial to achieve
higher or lower expression of immune-related gene sets is difficult to answer. On the one hand, a
strong pro-inflammatory response is generally considered as harmful; on the other hand, a stimulation
of the immune response could also have beneficial effects on local and systemic immune regulation [33].
In our earlier report of the FMT trial [11], we described that symptom improvement was found in the
allogenic FMT group compared to baseline, which was not the case in the autologous group. The
data presented in the current study shows that the host mucosal response was different after allogenic
compared to autologous FMT, which could possibly be an explanation for the symptom improvement.
Although allogenic FMT seemed to evoke an immune-related response while autologous FMT did not,
no serious adverse events or fever were reported after FMT [11], suggesting that the local activation of
immune-related pathways did not seem to result in a systemic immune response.
Differentially expressed gene sets were also found in the autologous group, in which patients
were treated with their own faecal material. More specifically, metabolism-related gene sets were
upregulated, and immune-related pathways downregulated. Our previously published results have
shown that autologous FMT also has an effect on the faecal and mucosal microbiota, possibly due
to the prior cleansing of the bowel or the handling of the faecal material during preparation for the
transplant. These changes in gut microbiota composition could be an explanation for an altered gene
expression response upon autologous FMT.
Not much is known about the effect of FMT on the mucosal host response. In vitro, it has been
shown that microbiota from a healthy donor alters the expression of numerous host genes in primary
human colonic epithelial cells [34]. A brief report showed that after repeated administration of FMT in
three paediatric UC patients, gene expression profiles in the colon mucosa had changed. The genes
downregulated after FMT were involved in leukocyte activation and mitotic cell cycle progression
processes [35]. However, it needs to be noted that in this study, baseline biopsies were collected from a
prepared bowel, while follow-up samples from two of the patients were collected from an uncleansed
bowel. In our study, all biopsies were collected from an uncleansed bowel at a standardised location in
the sigmoid.
While there is a lack of studies with regards to FMT, specific strains of the gut microbiota have
previously been shown to be able to modulate the gene expression of the host. After oral ingestion of the
commensal strain Lactobacillus plantarum, gene expression profiles in the duodenal mucosa of healthy
adults were altered, with several immune-related pathways affected [36]. Different probiotic species
have been shown to have different effects on duodenal gene expression [37], and even strain-dependent
effects have been described [38]. For example, the L. plantarum strain TIFN101 was shown to upregulate
gene expression pathways involved in T and B cell function, as well as antigen presentation, in the
duodenal mucosa of healthy subjects. However, in the same study other L. plantarum strains, CIP48 and
WCFS1, were shown to have a tendency to downregulate pathways involving antigen presentation
processes in the mucosa [38]. In our study, we identified several bacterial genera that correlated either
positively or negatively with immune-related gene sets, with different correlations found after allogenic
compared to autologous FMT. This substantiates again that FMT not only alters the intraluminal
intestinal ecosystem, but also specifically affects microbe–host interactions.
Even though the gut microbiota is a complex ecosystem, and we only had a limited study
population, we saw a rather consistent effect of FMT on the gene expression in the colonic mucosa. An
advantage of our study was that biopsies were collected at two time points after FMT, which confirms
the robustness of the results. In addition, we used a controlled study design. However, in future
studies, a separate control group that only receives bowel cleansing, as well as a different choice of
placebo, could give valuable insights. A limitation of this study was that blood samples were not
collected, and therefore only mucosal cytokine production was studied. No clear differences were
observed between cytokine levels after allogenic and autologous FMT, which could indicate that the
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protein production in biopsies were not affected by FMT, or that changes were not measurable due to
low detection levels.
5. Conclusions
In conclusion, we can show that the gut microbiota–host response is affected by FMT on the
mucosal gene expression level, and that there are clear differences in response to allogenic compared to
autologous FMT. How these effects contribute to a successful outcome in FMT therapy, especially with
regard to precision medicine, needs to be further elucidated in future studies.
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